In the 2023 NCCN Guidelines for liver cancer in the United States, it is proposed that Attilizumab (PD-L1) combined with bevacizumab (VEGF) should be considered as the first-line treatment for advanced unresectable liver cancer. This evidence concerns the gene VEGFA and liver cancer.